Ask AI

CCO Independent Conference Highlights of the 2025 ASH Annual Meeting: Global Perspectives on Emerging Data in Relapsed/Refractory CLL *

Enhance your understanding of novel targeted and cellular therapies for relapsed/refractory CLL to optimally integrate these strategies into patient care through a downloadable patient communication resource, downloadable capsule summaries, a podcast, and certified Medical Minute video modules.

Share

Program Content

6 Capsule Summaries

Activities

2L Pirtobrutinib
Pirtobrutinib as 2L Therapy for CLL/SLL Following  cBTKi Therapy: Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2025

BRUIN CLL-314
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2025

CaDAnCe 101
CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2025

BRUIN Update
BRUIN: Final Update From Phase I/II Trial of Pirtobrutinib for CLL/SLL Previously Treated With a Covalent BTKi
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2025

ALPINE Long Term Extension
Phase III ALPINE Long-Term Extension Study of Zanabrutinib in Patients With Relapsed or Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2025

Bexobrutideg in RR CLL
Phase Ia/b Trial of Bexobrutideg, a BTK Degrader, in Adults With Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2025

Activities

ALPINE Long Term Extension
ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2026

Expires: September 23, 2026

Bexobrutideg in RR CLL
BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL  
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 30, 2026

Expires: September 29, 2026

CaDAnCe 101
CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL  
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 27, 2026

Expires: September 26, 2026

BRUIN
Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi    
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 26, 2026

Expires: September 25, 2026

BRUIN CLL-314
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL  
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 27, 2026

Expires: September 26, 2026

Second Line Pirtobrutinib
Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321  
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 30, 2026

Expires: September 29, 2026

Activities

BTK Therapies in RR CLL
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2026

Expires: September 11, 2026

Activities

Patient’s Guide to CLL/SLL Advances
A Patient’s Guide to the Latest Clinical Advances in New Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma 
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 03, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly

*Decera Clinical Education is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.